Literature DB >> 21545327

Delays in treating patients with good grade subarachnoid haemorrhage in London.

Jonathan N Lamb1, Matthew Crocker, Matthew J Tait, B Anthony Bell, Marios C Papadopoulos.   

Abstract

BACKGROUND AND
PURPOSE: Spontaneous aneurysmal subarachnoid haemorrhage (SAH) is managed as a neurosurgical priority with guidelines and published literature emphasising the identification and the treatment of the ruptured aneurysm within 48 h of ictus. We audited the timing of management of good grade (WFNS 1 & 2) SAH in a neurosurgical unit in Greater London. We also reviewed the available services for treating SAH within Greater London.
MATERIALS AND METHODS: Retrospective audit of patients admitted with SAH to St. George's Hospital between 31 May 2007 and 31 May 2009 was performed. Prospective telephone and public record review of the catchment area and neurovascular provisions of the seven London neurosurgical units were assessed.
RESULTS: There were 141 WFNS grade 1 and 2 SAH patients admitted. Only a quarter were treated within 48 h of ictus. Patients destined for endovascular treatment waited significantly longer periods until treatment when compared with that of clipping group patients. The day of the week on which diagnostic angiography occurred was critical in determining treatment delays, probably due to the lack of routine provision of clipping at weekends and next day coiling services. We estimated that 440 good grade SAH are admitted per annum in Greater London. There are 20 neurovascular surgeons and 16 interventional neuroradiologists across seven neurosurgical units that routinely treat SAH.
CONCLUSIONS: We have identified significant delays in treating three quarters of good grade SAH patients in London. This appears to be due to a lack of next day treatment availability. A collaborative strategy between the seven London neurosurgical units could reduce treatment delays.

Entities:  

Mesh:

Year:  2011        PMID: 21545327     DOI: 10.3109/02688697.2010.544787

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  7 in total

Review 1.  Early endovascular treatment of subarachnoid hemorrhage.

Authors:  Jordi A Matias-Guiu; Carmen Serna-Candel
Journal:  Interv Neurol       Date:  2013-03

2.  Time intervals from aneurysmal subarachnoid hemorrhage to treatment and factors contributing to delay.

Authors:  Menno Robbert; Menno R Germans; Jantien Hoogmoed; H A Stéphanie van Straaten; Bert A Coert; W Peter Vandertop; Dagmar Verbaan
Journal:  J Neurol       Date:  2013-12-24       Impact factor: 4.849

3.  Timing of treatment of aneurysmal subarachnoid haemorrhage: are the goals set in international guidelines achievable?

Authors:  Abdurehman Choudhry; Daniel Murray; Paula Corr; Deirdre Nolan; Deirdre Coffey; Stephen MacNally; Alan O'Hare; Sarah Power; Matthew Crockett; John Thornton; Daniel Rawluk; Paul Brennan; Mohsen Javadpour
Journal:  Ir J Med Sci       Date:  2021-02-18       Impact factor: 1.568

4.  Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study.

Authors:  R Post; M R Germans; H D Boogaarts; B Ferreira Dias Xavier; R Van den Berg; B A Coert; W P Vandertop; D Verbaan
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

5.  Update of the ULtra-early TRranexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan.

Authors:  René Post; Menno R Germans; Bert A Coert; Gabriël J E Rinkel; W Peter Vandertop; Dagmar Verbaan
Journal:  Trials       Date:  2020-02-18       Impact factor: 2.279

6.  Timelines and rebleeds in patients admitted into neurosurgical care for aneurysmal subarachnoid haemorrhage.

Authors:  Angelika Sorteberg; Luis Romundstad; Wilhelm Sorteberg
Journal:  Acta Neurochir (Wien)       Date:  2021-01-06       Impact factor: 2.216

7.  Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial.

Authors:  Menno R Germans; René Post; Bert A Coert; Gabriël J E Rinkel; W Peter Vandertop; Dagmar Verbaan
Journal:  Trials       Date:  2013-05-16       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.